Introduction
MHC class II molecules are peptide receptors which display peptide fragments of degraded proteins on the surface of antigen-presenting cells to CD4 + T cells (1, 2) . The determination of the X-ray structure of the human class II molecule HLA-DR1 revealed that within the peptide binding site several class II residues form hydrogen bonds with the peptide main chain, thus forcing class II bound peptides into similar extended conformation despite differences in their primary sequence (3, 4) . The residues of DR1 which contact the peptide backbone are conserved in most human and mouse class II proteins (5) , indicating that all class II molecules may use the same hydrogen bonds to bind peptides. To increase the overall binding affinity, class II molecules make several bonds with peptide side chains that fit into binding pockets (4) . These binding pockets differ between different alleles. The anchor residues fitting into the pockets determine a peptide binding motif which is unique for each class II variant (for further references, see 6).
In contrast to the large body of information available for DR, relatively little is known about the interaction between peptides and DQ molecules (7) (8) (9) (10) . The molecular basis for binding of peptides to DQ molecules is important as several diseases are associated with certain DQ alleles. DQ2 shows a strong association to celiac disease (11) and insulindependent diabetes mellitus (12, 13) . We have previously shown that this molecule follows the general rules for peptide binding to class II molecules with respect to pH dependence and kinetic parameters (14) . Here we extend this study and identify a putative peptide binding motif for DQ2
Methods

Preparation of HLA-DQ2 molecules
An Epstein-Barr virus-transformed B lymphoblastoid cell line (CD114) from a HLA homozygous A1, B8, DR3, DQ2 [i.e. DQ(a1*0501, p1*02)] celiac disease patient was used as a source of DQ2 molecules. The DQ2 molecules were prepared mainly as described earlier (14) . The cells were grown in spinner cultures in RPMI 1640 containing 2 mM L-glutamine and 25 mM HEPES buffer supplemented with 10% heatinactivated horse serum (Gibco, Paisley, UK), penicillin (0.06 mg/ml; AL, Oslo, Norway) and streptomycin (0.1 mg/ ml; Heyl, Berlin, Germany). The cells were lysed for 30 min at 0°C at a concentration of 10 8 cells/ml in PBS containing 1% Nonidet P-40 (NP-40), 5 mM Na-orthovanadate, 25 mM iodoacetamide and 1 mM phenylmethylsulphonyl fluoride (PMSF) (15) . The lysates were cleared for nuclei and debris by centrifugation at 4°C and stored at -70°C until used.
The DQ2 molecules were essentially purified as described earlier (14, 16) , using the mouse anti-DQ2 mAb 2.12.E11 (17) covalently coupled to Protein A-Sepharose CL-4B (18) . Lysates of 10 10 cells were passed sequentially through a Protein A-Sepharose CL-4B precolumn and the 2.12.E11 column. The 2.12.E11 column was extensively washed with PBS containing 0 1% SDS and 0.5% NP-40, and subsequently equilibrated with PBS containing 1% p-octylglucoside. The DQ2 molecules were eluted with 50 mM diethylamine (pH 11.5) containing 0.15 M NaCI and 1% p-octylglucoside The eluates were immediately neutralized with 2 M Tns, pH 6 3 (120 of the eluate volume), concentrated by vacuum dialysis (Sartourius, Gottingen, Germany) and finally dialysed against PBS containing 1% p-octylglucoside and 0.1% NaN 3 . The protein content was determined by a BCA protein assay (Pierce, Oud-Beijerland, The Netherlands) and the purity was confirmed by SDS-PAGE. The purified DQ2 molecules were stored at 4°C.
Peptides
Most of the synthetic peptides were prepared as described earlier (14) . The OVA 267-276Y peptides with S 26 g, V 272 and E275 substituted with other amino acids were synthesized by Cambridge Research Biochemicals Multiple Peptide Synthesis Service (Cambridge Research Biochemicals, Cheshire, UK). The peptides were aliquoted and lyophilized before storage at -20°C. When used all the peptides except the polyalanine analogue were solubilized and diluted in PBS. In experiments where the polyalanine analogue was tested, the peptides were solubilized in DMSO and further diluted with PBS giving a concentration in the reaction mixture of 1.67% DMSO.
Peptide-DO2 binding assays
Purified DQ2 molecules (200-500 nM) were incubated with a radiolabelled Mycobacterium bovis 65 kDa heat shock protein derived peptide (KPLLIIAEDVEGEY; MB 65 kDa 243-255Y) peptide (25,000 c.p.m.; 1-5 nM) for 24 h at 37°C (14) . Furthermore the reaction mixture contained PBS buffered with citrate phosphate to pH 4.9, 0.05% NP-40 and a mixture of protease inhibitors [1 mM PMSF, 1.3 mM 1,10 phenanthroline, 73 nM Pepstatin A, 8 mM EDTA, 1 mM A/-ethylmaleimide, 135 p.M Mx-p-tosyl-L-lysine chloromethyl ketone, 142 |xM Ntosyl-L-phenylalanine chloromethyl ketone (Sigma, St Louis, MO)]. The peptide was radiolabelled using the chloramine T method (19) (2 ^g peptide/0.5 mCi 125 I) and stored at 4°C in PBS containing 2% ethanol.
After incubation peptide bound to DQ2 and free peptide were separated on Sephadex G25 superfine spun columns (20) . The radioactivity was counted in a y-counter (Wallac, Turku, Finland), and the fraction of peptide bound to DQ2 was calculated. All experiments were performed in duplicates and repeated one or more times, usually with different DQ2 preparations The variation between duplicate samples was usually <10%.
To test binding of several unlabeled peptides, competitive inhibition experiments were performed. Inhibiting peptides were then mixed with labelled peptide and DQ2 molecules at the start of the binding assay. The inhibiting peptides were tested in concentration from 16.7 nM to 166.7 [iM in 10-fold steps and the concentration required to give 50% inhibition (IC 50 ) was calculated. Relative binding capacity (RBC) for each tested peptide was calculated as the ratio of the IC50 of the reference peptides to the IC 50 of the tested peptide.
Results
Truncation analysis of the good DQ2 binder OVA 258-276Y
A panel of 47 peptides differing in length and sequence had previously been screened for binding to DQ2 and DR3 (14) The OVA 258-276Y peptide bound relatively well to DQ2 but very weakly to DR3 and was thus selected for further characterization of the binding of peptides to DQ2. This peptide inhibits the response of an antigen-specific DQ2 restricted T cell clone indicating that it binds to the peptide binding site of DQ2 (Gjertsen et al., unpublished work).
To identify a the minimal core binding region of the OVA 258-276Y, peptide truncation analysis was performed ( 
Single ammo acid substitution analysis of the OVA 267-276Y peptide
Analogues of the OVA 267-276Y peptide with single alanine substitutions through the sequence of the peptide were tested for binding to DQ2 together with the reference OVA 267-276Y peptide (Fig. 2a) Alanine substitutions usually have an effect on the binding of a peptide to an HLA molecule if the original residues is specifically interacting with the HLA molecule because of its size or charge When either \J 2 72. E275
or tn e C-terminal Y were replaced with alanine, a 10-fold decrease in binding capacity was detected. Thus, these amino acid residues seemed to be important for binding of the OVA 267-276Y peptide to DQ2. Another interesting observation was that the analogue with the N 2 7i substitution showed increased binding. This indicates that N 2 7i in the core binding region may exert a negative effect on binding of this peptide to DQ2.
A polyalanine peptide containing the residues V 2 72, E 2 7 5 and C-terminal Y identified by the single alanine substitution analysis was then synthesized and tested for binding to DQ2 (Fig. 2b ) This polyalanine peptide bound 3-fold better to DQ2 than the original OVA 267-276Y peptide. The stronger binding was probably caused by removal of residues like N 271 which could have negative effects on the binding of the peptide to DQ2. A similar polyglycine analogue showed poor binding when tested for binding to DQ2 (167 u.M resulted in only 20% inhibition of the binding of the indicator peptide). The conformational possibilities of polyglycine are known to be significantly greater than for polyalanine (21) . This could explain the lower affinity of the polyglycine analogue
The importance of V 272 , E275 and the C-terminal Y was further studied by extensive substitutions in each position. No reduction in binding was observed when the C-terminal Y was substituted with large hydrophobic residues (Fig 3a) , whereas smaller hydrophobic, polar or charged residues all had a negative effect on binding compared with Y. In particular K was unfavourable in this position. V 272 (Fig 3b) (Fig. 3b ) could be substituted with the other negatively charged D without significant loss in binding, whereas L and A were weakly deleterious for binding. A substitution with the positively charged K also in this position almost eliminated the binding of the peptide. Deletion of the C-terminal Y resulted in a 10-fold loss in binding (Fig 3a) The same was also observed when the Cterminal Y of another peptide (the indicator peptide MB 65 kDa 243-255Y, KPLLIIAEDVEGEY) was deleted (results not shown). This indicates that bulky hydrophobic residues in the C-terminal part of the binding region probably are important also for binding of other peptides to DQ2
DO2 peptide binding motif
The role of W 26 7 has also been studied (results not shown). Analogues in which W 267 was substituted with various amino acids (F, A, K, D and N) and an OVA 268-276Y peptide with N-terminal acetylation all bound to the same extent to DQ2 as the original OVA 267-276Y peptide.
We next tested whether shortening the length between two anchor residues could negatively influence the binding of the peptide to DQ2. This was done by making an analogue in which the arginine (R 2 76) between E 275 and the C-terminal Y was deleted Near a 100-fold reduction in binding was observed when the binding of this analogue was compared with the original OVA 267-276Y peptide (Fig. 3c) . 
Discussion
In order to describe the structural requirements for binding of peptides to DQ(a1*0501, pi*02), i.e. DQ2, we have performed a detailed examination of the binding of a high-affinity DQ2 binder (OVA 258-276Y) (14) . The minimal core binding region, defined as the minimal region giving optimal peptide binding, comprised the sequence W2 6 7T2 68 S 269 S27oN27iV272M273E274E275R276Y-Substitution analysis revealed, as we discuss later, that the Cterminal Y was directly involved in the specific binding of the peptide. The N-terminal W 2 67, however, did not seem to contribute to the specific binding. The side chain of this residue could be exchanged with unpolar, polar and charged side chains or even only with an acetyl group without disrupting the binding potential of the peptide. This observation indicates that the importance of the N-terminal W 2 67 more reflects a minimal length requirement of the peptide backbone rather than the need for specific amino acid side chains in this position. A similar phenomenon of length requirement has been demonstrated for DR3 (22) .
Analysis with single alanine substituted peptides indicated that the side chains of V 27 2, E275 and the C-terminal Y played important roles for binding of the OVA 267-276Y peptide to DQ2. Testing a poly(A) analogue containing V, E and Y in the correct positions corroborated that these amino acids were anchor residues. The result of the latter experiment resembles earlier observations made for several different DR molecules when these have been tested with simplified peptides that contain anchor residues (23, 24) . Further substitution analysis showed that V 272 may be replaced with D and E without disrupting the binding. Substitution of this residue in particular with K but also W, however, seriously impaired the peptide binding. For E275, a substitution with D was accepted while a substitution with K was not allowed The C-terminal Y could be substituted with bulky hydrophobic residues, whereas in particular K was unfavourable.
The majority of the DR1 residues which according to the X-ray structure form hydrogen bonds with the peptide main chain, are conserved between DR1 and DQ2 (5). One may thus assume that similar to DR1, peptides are bound to DQ2 in an extended conformation The importance of a correct spacing between the anchor residues, as shown by the impaired binding of an analogue with a deletion of R2 76 , supports the notion that the OVA 267-276Y peptide binds to DQ2 in an extended conformation.
The three-dimensional structure of DR1 and the influenza virus peptide denotes five binding pockets (4) here termed the P1, P4, P6, P7 and P9 pockets. The P1 and P9 pockets harbour the side chains of the N-terminal (P1) and C-terminal (P9) anchor residues respectively (25) . Hypothetically, the side chain of the C-terminal Y of the OVA 267-276Y peptide may fit into the P9 pocket of DQ2. If so, the side chain of V 272 may fit into the P7 pocket and the side chain of E 275 may fit into the P4 pocket (P7 and P4 anchor residues). Evidence in favour of this model may be obtained from comparison of the primary HLA sequences and pocket specificity of two DR4 variants [DR(<x, (31*0401), DR(<x, (31*0402) (26, 27) ] and DQ2 Hammer and co-workers have by means of peptide libraries characterized the amino acids exerting positive and negative effects for binding to these two DR molecules. The charge of residues (370 and [371, that are central contact residues of the P4 pocket, differs between the two variants and this seems to influence the specificity of the pocket. In particular this has been shown for (371 (27) Principally, a positively charged residue in (371 (K in DR(31*O4O1) influences the pocket to repel positively charged and attract negatively charged residues, whereas negatively charged amino acids in (370 and (371 (D and E respectively in DR(31*0402) influence the pocket to repel negatively charged and attract positively charged residues (Table 1) 
P7 pocket DR(a,p1*0101) DR(a,pi*0401) (27) DR(a,pi*0402) (27) P28 P38 P47 061 P65 067 |371
The assignment of residues assumed to create the pockets is based on the crystal structure of DR1 and an influenza virus haemagglutinin (4) . HLA residues that do not directly contact the peptide in this structure, but which may directly contact a peptide in other class ll-peptide complexes, are shown in parentheses.
b Non-charged residues may have advantageous or deleterious effects in these positions but are not shown here.
D02 peptide binding motif 181 (J77. This HLA residue does not contact the peptide in the DR1/influenza haemagglutinin peptide crystal but it may contact peptide in other class ll-peptide combinations (4) . Altogether, the net charge of the residues assumed to create the P4 pocket in DQ(a1*0501, |31*O2) is intensely positive and based on the above reasoning this would result in a pocket that would repel positively charged and attract negatively charged side chains. This is in complete accordance with our observations. The same rational may be applied for the P7 pocket although the experimental basis with DR4 molecules is weaker in this case (Table 1) . A charge-charge interaction may explain why the putative P7 anchor of the OVA 267-276Y peptide (E 275 ) may be substituted with D but absolutely not with K. It should be emphasized that the P4 and P7 pockets do allow accommodation of non-charged side chains both in the DR4 variants and probably also in DQ2. It may thus be that the phenomenon of repulsion of side chains with equal charge as the pocket residues is the most important factor for determining binding specificity of these pockets in DQ2.
In the P9 pocket of DR1 there is a salt bridge between R in cc76 and D in (357 DR(cc, (51*0405), which has a non-D (i.e. S) in position (J57 and thus probably not the above mentioned saltbridge, prefers negatively charged side chains as the P9 anchor (28, 29) , whereas positively charged side chains in the P9 anchor position are unfavourable (29) . DQ2 has also a non-D in position (357 (i.e. A). As has been suggested for DR(a, p1*0405), one may speculate that the unfavourable effect of positively charged residues (R and K) as a P9 anchor for peptide binding to DQ2 may relate to repulsion between R in residue cc79 of DQ2 (cx76 in DR) and these peptide residues.
Peptides binding to DR1 generally have critical bulky hydrophobic anchor residues in P1 (23, (30) (31) (32) . To examine whether bulky hydrophobic amino acid residues could be favourable in position P1 also for peptide binding to DQ2, we tested an analogue with an F substituted for S 2 69 (results not shown). In fact, this analogue showed stronger binding than the original peptide, suggesting that also for DQ2, bulky hydrophobic residues may be favourable in position P1. However, this notion must be verified in further experiments. At any rate, our data do not indicate that the P1 anchor is as critical for binding of peptides to DQ2 as this anchor is for binding of peptides to most DR molecules (25) .
Collectively, our data suggest that for peptide binding to DQ2, negatively charged and hydrophobic aliphatic residues are preferred to aromatic and positively charged residues in P4 In P7 negatively charged residues are preferred to positively charged residues. In P9, it seems to be advantageous to have bulky aromatic or hydrophobic aliphatic residues, whereas positively charged residues exert a negative effect. The characteristics of the different anchors are summarized in Table 2 . We have also aligned peptides which we previously have identified as high-affinity DQ2 binders according to this putative binding motif ( Table 2 ). All the peptides can be aligned reasonably well according to the proposed motif.
Previously a DQ2 peptide binding motif with predominance of K in relative position i, I and A in relative position i + 3 and F and K in relative position i + 8 has been identified by pool sequencing (10) . This motif is in partially in agreement with ours with an aliphatic residue in P4 (i.e I and A) and a bulky hydrophobic (i.e. F) in P9. Notably, however, the K in P9 is not in keeping with our results
During the last few years general principles for peptide binding to MHC class II molecules have been uncovered. Our results indicate that peptide binding to DQ2 seems to follow these general principles Our description of a putative DQ2 binding motif is a step towards a complete characterization of the DQ2 binding motif that will allow T cell epitope prediction. This will hopefully help us to achieve a better understanding of the molecular basis for DQ2-associated diseases like celiac disease and insulin-dependent diabetes mellitus
